Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,013 | 605 | 84.9% |
| Travel and Lodging | $1,828 | 5 | 14.1% |
| Education | $124.78 | 7 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Luitpold Pharmaceuticals Inc | $1,564 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,441 | 96 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,424 | 32 | $0 (2024) |
| Amgen Inc. | $1,280 | 85 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $917.02 | 56 | $0 (2024) |
| PFIZER INC. | $755.41 | 43 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $752.56 | 57 | $0 (2024) |
| Gilead Sciences, Inc. | $374.42 | 30 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $344.72 | 20 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $340.25 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,560 | 79 | Novartis Pharmaceuticals Corporation ($289.06) |
| 2023 | $1,464 | 77 | Novartis Pharmaceuticals Corporation ($219.02) |
| 2022 | $1,059 | 57 | Bayer HealthCare Pharmaceuticals Inc. ($156.81) |
| 2021 | $1,034 | 60 | Amgen Inc. ($208.91) |
| 2020 | $461.64 | 27 | Amgen Inc. ($73.39) |
| 2019 | $1,641 | 100 | Novartis Pharmaceuticals Corporation ($233.75) |
| 2018 | $2,451 | 102 | Merck Sharp & Dohme Corporation ($888.72) |
| 2017 | $3,295 | 115 | Luitpold Pharmaceuticals Inc ($1,564) |
All Payment Transactions
617 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: DIABETES | ||||||
| 11/22/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.06 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $31.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: DIABETES | ||||||
| 10/11/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/08/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Not Applicable | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $6.94 | General |
| Category: DIABETES | ||||||
| 09/25/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $30.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Cardiology | ||||||
| 09/06/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/02/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $53.10 | General |
| Category: LUX-Dx_CRM | ||||||
| 08/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,719 | 2,348 | $548,402 | $126,139 |
| 2022 | 23 | 2,535 | 3,385 | $593,344 | $142,335 |
| 2021 | 25 | 2,219 | 3,014 | $489,062 | $131,059 |
| 2020 | 25 | 2,575 | 3,101 | $442,021 | $135,120 |
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 307 | 456 | $109,757 | $39,296 | 35.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 215 | 224 | $147,862 | $27,492 | 18.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 145 | 147 | $56,977 | $19,455 | 34.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $15,837 | $6,173 | 39.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 399 | 550 | $84,838 | $5,398 | 6.4% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 37 | 37 | $12,995 | $5,088 | 39.2% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 20 | 34 | $16,086 | $3,325 | 20.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 15 | 60 | $4,421 | $2,748 | 62.2% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 39 | 42 | $9,568 | $2,711 | 28.3% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 19 | 19 | $6,312 | $2,108 | 33.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 23 | 37 | $8,878 | $1,813 | 20.4% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 12 | 25 | $9,871 | $1,541 | 15.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 222 | 280 | $9,660 | $1,394 | 14.4% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 11 | 24 | $8,095 | $1,159 | 14.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 28 | 28 | $5,023 | $1,150 | 22.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 12 | 154 | $3,357 | $1,130 | 33.7% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 18 | 18 | $8,306 | $934.38 | 11.3% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 38 | 41 | $7,265 | $689.02 | 9.5% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 18 | 26 | $4,341 | $684.98 | 15.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 15 | 15 | $5,340 | $663.56 | 12.4% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Office | 2023 | 35 | 38 | $5,699 | $662.60 | 11.6% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 20 | 21 | $3,155 | $271.70 | 8.6% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 20 | 21 | $4,759 | $249.81 | 5.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 341 | 496 | $119,357 | $42,331 | 35.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 215 | 217 | $144,181 | $27,551 | 19.1% |
About Dr. Michael Hong, MD
Dr. Michael Hong, MD is a Cardiovascular Disease healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760595771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Hong, MD has received a total of $12,966 in payments from pharmaceutical and medical device companies, with $1,560 received in 2024. These payments were reported across 617 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($11,013).
As a Medicare-enrolled provider, Hong has provided services to 9,048 Medicare beneficiaries, totaling 11,848 services with total Medicare billing of $534,653. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location Buffalo, NY
- Active Since 08/16/2006
- Last Updated 12/01/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760595771
Products in Payments
- INJECTAFER (Drug) $1,593
- ENTRESTO (Drug) $1,125
- Repatha (Biological) $1,067
- MK-1242 (Drug) $888.72
- XARELTO (Drug) $752.56
- ELIQUIS (Drug) $653.18
- JARDIANCE (Drug) $564.60
- VERQUVO (Drug) $517.55
- PRADAXA (Drug) $352.42
- BRILINTA (Drug) $306.48
- LEQVIO (Drug) $300.88
- Corlanor (Drug) $212.62
- PRALUENT (Drug) $209.36
- LifeVest (Device) $209.00
- Impella (Device) $194.35
- CHANTIX (Drug) $171.99
- Arcalyst (Drug) $156.51
- Kerendia (Drug) $145.77
- MULTAQ (Drug) $135.36
- Hillrom - Cardiac Ambulatory Monitor (Device) $123.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Buffalo
Dr. Kenton Forte, M.d, M.D
Cardiovascular Disease — Payments: $475,136
William Boden, Md, MD
Cardiovascular Disease — Payments: $244,563
Anne Curtis, Md, MD
Cardiovascular Disease — Payments: $227,013
Dr. Salvatore Calandra, Md, MD
Cardiovascular Disease — Payments: $72,862
Dr. Stanley Fernandez, M.d, M.D
Cardiovascular Disease — Payments: $53,366
Joseph Gelormini, M.d, M.D
Cardiovascular Disease — Payments: $14,839